Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Takeda Adds Maverick Therapeutics

Takeda Adds Maverick Therapeutics

The pharmaceutical giant Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) is back with a new acquisition. The company has announced the acquisition of Maverick Therapeutics, Inc for a pre-negotiated upfront payment as well as potential development and regulatory milestones totaling up to $525 million. This acquisition follows a multi-year collaboration between Takeda and Maverick, signed in 2017.  Maverick Therapeutics is a privately held biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies. Its lead candidates are MVC-280 (now TAK-280) and MVC-101 (now TAK-186). TAK-186 is currently in a Phase 1/2 study for the treatment of EFGR-expressing solid... Read More »
WELL Health Builds Digital Health Portfolio

WELL Health Builds Digital Health Portfolio

The Canadian-based company WELL Health Technologies Corp. (TSX.V: WELL) went on an acquisition spree in 2020, adding a plethora of smaller, digital health companies to build up its product portfolio. Last week, they continued that spree, announcing the acquisition of Intrahealth, a Vancouver-based healthcare software company. Intrahealth provides a suite of flexible software and electronic medical record solutions to a wide variety of customers including health authorities, hospitals, public health outpatient centers, community health, home care, ambulatory care and diverse health care professionals.  WELL Health paid roughly CAD 15.4 million consisting of CAD 10.6 million in cash, CAD... Read More »
Quest Diagnostics Acquires Lab Division from Mercy

Quest Diagnostics Acquires Lab Division from Mercy

In an effort to expand its network, Quest Diagnostics (NYSE: DGX) has announced a deal with not-for-profit Mercy, a multi-state healthcare system. Quest is acquiring the health system’s outreach laboratory services business, which currently operates from 29 hospital laboratories and two independent clinic laboratories in Arkansas, Kansas, Missouri and Oklahoma.  No terms were disclosed in the all-cash transaction, but under the agreement, testing associated with outreach lab services will transition to the Quest Diagnostics full-service laboratory in Lenexa, Kansas, and a network of rapid response laboratories across the region. Mercy will continue to wholly own and operate its hospital... Read More »
Health Care M&A Deals, March 12, 2021

Health Care M&A Deals, March 12, 2021

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week by disclosed price is DocGo’s reverse merger with Motion Acquisition Corp. (NASDAQ: MOTN), a special purpose acquisition company to create a publicly traded entity. DocGo, based in New York City, provides last-mile telehealth and integrated medical mobility services. Its medical mobility services offer on-demand service response and real-time... Read More »

The State of the Rehabilitation M&A Market

Throughout 2020, there wasn’t much to write about in the Rehabilitation sector. The industry was under regulatory pressure from CMS in the beginning of 2020, and then Covid-19 came around, making things even more difficult. Social distancing guidelines hindered in-person appointments, and we imagine that the effects of surgery cancellations at hospitals trickled down into this sector as well. U.S. Physical Therapy, Inc. (NYSE: USPH), one of the largest rehabilitation providers, saw a 13.8% drop in net patient revenue in 2020 compared with 2019, for instance. However, It was more difficult to discern the effects in the M&A market. The sector barely breaks double-digit deal volume on a... Read More »
CROs Are Back in Demand

CROs Are Back in Demand

Last year was not kind to contract research organizations (CROs). CROs typically provide discovery and development services to companies in the Medical Device, Pharmaceutical and Biotechnology sectors, conducting clinical trials and providing a wealth of R&D support. Demand for their services have seen a gradual rise over the last decade for a variety of reasons. An increasing number of start-ups have popped up in the Biotechnology sector, and they don’t have the resources or infrastructure that major players would have to oversee the complex R&D needed to bring a drug to market, so they often outsource much of that task to CROs. Second, big pharma and biotech are increasingly... Read More »
Kindred Healthcare Adds Two Rehab Hospitals

Kindred Healthcare Adds Two Rehab Hospitals

The healthcare services giant Kindred Healthcare, LLC is back in the M&A market. Much of the company’s activity has focused on partnerships and new development projects, but now Kindred is adding two rehabilitation hospitals with two separate joint ventures.  The first deal was announced in partnership with Texas Health Resources, a faith-based, not-for-profit health system. The two companies have jointly taken control of Everest Rehabilitation Hospital of Keller, a 36-bed rehabilitation hospital located in the northern suburbs of Fort Worth, Texas that just opened in December 2020. The hospital will be renamed Texas Rehabilitation Hospital of... Read More »
Amgen Acquires Five Prime Therapeutics

Amgen Acquires Five Prime Therapeutics

The biotech giant Amgen, Inc. (NASDAQ: AMGN) has announced a new deal for Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. The company collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development.  Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. The dollar-per-share amount is a 78% premium to Five Prime’s closing price on March 3, 2021. The transaction comes out to an estimated 232x Five Prime Therapeutics’ annualized revenues. However, the company... Read More »
Health Care M&A Deals, March 12, 2021

Health Care M&A Deals, March 5, 2021

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week by disclosed price is Amgen’s acquisition of Five Prime Therapeutics for $1.9 billion. Five Prime Therapeutics Five Prime Therapeutics is a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. The company collaborates with leading global pharmaceutical companies and has therapies in... Read More »
Health Care M&A Deals, March 12, 2021

Health Care M&A Deals, February 26, 2021

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week by disclosed price is ICON plc’s acquisition of PRA Health Sciences, Inc. for $12.5 billion. PRA is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform... Read More »